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Abstract
Objective: Diagnosis of frontotemporal dementia (FTD) is complicated by the
overlap of clinical symptoms with other dementia disorders. Development of
robust fluid biomarkers is critical to improve the diagnostic work-up of FTD.
Methods: CSF concentrations of placental growth factor (PlGF) were measured
in the discovery cohort including patients with FTD (n = 27), Alzheimer dis-
ease (AD) dementia (n = 75), DLB or PDD (n = 47), subcortical vascular
dementia (VaD, n = 33), mild cognitive impairment that later converted to AD
(MCI-AD, n = 34), stable MCI (sMCI, n = 62), and 50 cognitively healthy con-
trols from the Swedish BioFINDER study. For validation, CSF PlGF was mea-
sured in additional independent cohort of FTD patients (n = 22) and controls
(n = 18) from the Netherlands. Results: In the discovery cohort, MCI, MCI-
AD, AD dementia, DLB-PDD, VaD, and FTD patients all showed increased
CSF levels of PlGF compared with controls (sMCI P = 0.019; MCI-AD
P = 0.005; AD dementia, DLB-PDD, VaD, and FTD all P < 0.001). PlGF levels
were 1.8–2.1-fold higher in FTD than in AD, DLB-PDD and VaD (all
P < 0.001). PlGF distinguished with high accuracy FTD from controls and
sMCI performing better than tau/Ab42 (AUC 0.954–0.996 versus 0.564–0.754,
P < 0.001). A combination of PlGF, tau, and Ab42 (tau/Ab42/PlGF) was more
accurate than tau/Ab42 when differentiating FTD from a group of other
dementias (AUC 0.972 vs. 0.932, P < 0.01). Increased CSF levels of PlGF in
FTD compared with controls were corroborated in the validation cohort. Inter-
pretation: CSF PlGF is increased in FTD compared with other dementia disor-
ders, MCI, and healthy controls and might be useful as a diagnostic biomarker
of FTD.
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Introduction
Frontotemporal dementia (FTD) is one of the most com-
mon early-onset dementia with a reported prevalence rate
of 3–26% in demented people with disease onset before
65 years of age.1 The core features of FTD are progressive
deterioration in behavior, executive function or language
caused by neuronal loss in frontal and anterior temporal
cortices.2,3 Based on clinical presentation FTD is broadly
classified into behavioral-variant FTD (bvFTD), semantic-
variant primary progressive aphasia (svPPA or semantic
dementia (SD)) and nonfluent variant primary progres-
sive aphasia (nfvPPA or PNFA).4,5 Neuropathologically,
FTD is characterized by either intraneuronal inclusions
containing tau, TAR DNA-binding protein with molecu-
lar weight 43 kDa (TDP-43), or fused-in-sarcoma (FUS)
proteins.1,6 Approximately 10–20% of all FTD cases show
autosomal dominant inheritance.7 The majority of genetic
FTD is due to mutations in MAPT,8–10 GRN,11,12 or
C9orf7213–15 genes, which are associated with accumula-
tion of tau (in MAPT mutation carriers) or TDP-43 (in
GRN and C9orf72 mutation carriers) inclusions. Diagnosis
of FTD is challenging because of the heterogeneity of clin-
ical presentations, symptomatic overlap with other neu-
rodegenerative disorders and difficulties to distinguish
bvFTD, particularly in early stages, from primary psychi-
atric conditions which leads to long periods of diagnostic
delay.16 Although progression of symptoms and imaging
biomarkers may provide important diagnostic clues, there
is a need for more cost-efficient and less time-consuming
fluid biomarkers that could improve differential diagnosis
of FTD.17 In this study, we identified placental growth
factor (PlGF) as a new candidate biomarker of FTD. PlGF
is a member of the vascular endothelial growth factor
(VEGF) family, originally described in placenta but later
found to be expressed in other organs.18 In addition to
its regulatory role in pregnancy, accumulating evidence
point to the biological effects of PlGF in pathological
inflammation and angiogenesis associated with ischemia,
hematologic diseases, and cancer.19 Several studies have
implicated PlGF in central nervous system disorders.
Upregulation of PlGF mRNA and protein in the brain
has been shown in mouse models of ischemia.20,21 Fur-
thermore, we have demonstrated elevated CSF levels of
PlGF in Parkinson’s disease (PD), Parkinson’s disease
dementia (PDD) and dementia with Lewy bodies
(DLB).41 Here, we measured cerebrospinal fluid (CSF)
levels of PlGF in FTD and four major forms of neurode-
generative disorders with dementia. The discovery cohort
included a total of 278 patients with FTD, AD, DLB,
PDD, and VaD as well as stable MCI (sMCI), MCI that
progressed to AD (MCI-AD) and 50 cognitively healthy
controls. We validated findings in the discovery cohort in
additional independent cohort of FTD patients (n = 22)
and controls (n = 18) from the Netherlands. Finally, in
the discovery cohort, we assessed the performance of
PlGF as a biomarker distinguishing FTD from controls or
patients with other dementias.
Subjects and Methods
Study participants
Discovery cohort: Seventy-five patients with AD, 47
patients with DLB-PDD, 33 patients with VaD, 27 patients
with FTD (25 bvFTD, 2 SD) and 50 healthy controls were
recruited at the Memory Clinic of Skane University Hospi-
tal in Malm€o, Sweden. This cohort also included 96 indi-
viduals (recruited from the same clinic) with a baseline
diagnosis of MCI. After an average clinical follow-up per-
iod of 5.7 years (3.0–9.6), 34 of those had converted to
AD (MCI-AD), whereas 62 remained cognitively stable
(sMCI). All study participants were assessed by medical
doctors with extensive experience in cognitive disorders.
All patients with a clinical syndrome of dementia met the
DSM-IIIR criteria for dementia22 combined with the
NINCDS-ADRDA criteria for AD,23 the NINDS-AIREN
criteria for VaD24 or criteria of probable DLB according to
the 2005 consensus criteria.25 FTD patients were diagnosed
according to Rascovsky (bvFTD)26 or Neary (SD) crite-
ria.27 The FTD patients were recruited either from clinical
practice or from a longitudinal FTD research study.28 All
patients had minimum cerebral computed tomography
(most often MRI) as imaging modality, and CSF analysis
of AD biomarkers were used as exclusion criteria with in-
house cutoffs for clinical routine practice established at the
Clinical Neurochemistry Laboratory, University of
Gothenburg, Sweden following strict procedures for qual-
ity control to assure long-term stability of biomarker
levels.29 Of the 27 bvFTD patients, 18 were probable
bvFTD, and 3 possible bvFTD, 4 definite bvFTD (3 by
confirmation of TDP-43 pathology postmortem and one
C9orf72 repeat expansion carrier), and 2 SD. Patients with
MCI at baseline had to fulfill the criteria advocated by
Petersen.30 The healthy participants were not allowed to
have any cognitive complaints or any significant neurolog-
ical or psychiatric illness and they needed to have a well-
preserved general cognitive functioning. A careful clinical
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interview, together with an assessment of global function
(Mini-Mental State Examination, MMSE), delayed recall
(Alzheimer’s Disease Assessment Scale Cognitive Sub-
scale, ADAS Cog, 10 word list delayed recall), attention
(a quick test of cognitive speed, AQT) and visuospatial
and executive function (cube-drawing test and clock
test), was done to rule out mild cognitive impairment.
AD biomarkers were not considered in the diagnostic
process. The characteristics of the cohort are given in
Table 1.
Validation cohort: This independent cohort included
18 cognitively healthy controls, 22 patients with FTD (14
bvFTD, 6 SD, 2 PNFA) and 5 presymptomatic individuals
with a GRN mutation that were recruited at the memory
clinic of the Erasmus Medical Center. FTD patients were
diagnosed according to Rascovsky (bvFTD)26 or Gorno-
Tempini (SD and PNFA) criteria.31 Healthy controls and
presymptomatic GRN mutation carriers were ascertained
in our longitudinal FTD-RisC cohort in which asymp-
tomatic first-degree relatives (at-risk individuals) of
patients with autosomal dominant FTD are followed.32
Screening of the familial mutation is performed to divide
at-risk individuals into presymptomatic mutation carriers
and healthy controls, and investigators remain blinded to
individual mutation status. The characteristics of the
cohort are given in Table 2.
The design of this study has been approved by the
Local Ethics Committee of Lund University, Sweden and
by the Local Ethics Committee of Erasmus Medical Cen-
ter, the Netherlands and the study procedure was con-
ducted in accordance with the Helsinki Declaration. All
study participants (or legal representatives) gave their
written informed consent to research.
CSF sampling and biological assays
For all patients and controls, CSF samples were drawn
with the patients nonfasting. CSF was collected in
polypropylene tubes and mixed gently to avoid gradient
effects. All samples were centrifuged within 30 min at
+4°C at 2000g for 10 min to remove cells and debris.
Samples were stored in aliquots at 80°C pending
biochemical analysis. CSF PlGF was measured using
electrochemiluminescence immunoassay as per the
Table 1. Discovery cohort, demographic data, clinical characteristics, and CSF levels of PlGF.
Control
(n = 50)
sMCI
(n = 62)
MCI-AD
(n = 34)
AD
(n = 75)
DLB-PDD
(n = 47)
VaD
(n = 33)
FTD*
(n = 27)
Age 74.2 (5.1) 69.2 (7.5)a 74.9 (7.7)b 76.4 (7.4)b 74.5 (6.3)b 75.9 (7.9)b 70.1 (6.6)a,c,d,e,f
Sex, (% female) 72% 56% 65% 68% 40%a,c,d 46%a 44%a,d
APOE
1 or 2 e4 alleles
27% 47%a 82%a,b 65%a,b 54%a,c 25%b,c,d,e 27%c,d
MMSE 29.0 (1.0) 28.2 (1.2) 26.4 (1.7)a,b 19.5 (3.3)a,b,c 21.9 (5.1)a,b,c,d 21.7 (4.4)a,b,c,d 22.8 (6.3)a,b,c,d
Ab42, pg/mL 695 (282) 486 (201)a,b 317 (78)a,b 260 (105)a,b 340 (173)a,d 396 (190)a,b,d 709 (295)b,c,d,e,f
Ab40, pg/mL 5206 (1545) 3821 (1377)a 4232 (1345)a 3899 (1376)a 3170 (1137)a,b,c,d 3238 (1285)a,c,d 4509 (1660)a,b,e,f
tau, pg/mL 443 (165) 437 (175) 645 (227)a,b 766 (266)a,b,c 472 (171)c,d 441 (192)c,d 385 (214)c,d
PlGF, pg/mL 54.8 (15.8) 64.1 (31.8)a 70.5 (20.8)a 79.5 (33.6)a 89.5 (41.4)a,b 94.2 (40.5)a,b,c 166.7 (63.4)a,c,d,e,f
AD, Alzheimer disease; DLB-PDD, dementia with Lewy bodies or Parkinson’s disease with dementia; F, female; FTD, frontotemporal dementia;
sMCI, mild cognitive impairment; MCI-AD, MCI that progressed to AD; MMSE, Mini Mental State Examinations; PlGF, placental growth factor;
VaD, vascular dementia.
*FTD group included 25 bvFTD (1 patient with C9orf72 mutations and 3 patients with TDP-43 positivity neuropathologically) and 2 SD cases.
APOE data were only available from 11 FTD patients.
Data are shown as mean (SD, n) unless otherwise specified. Demographic factors and clinical characteristics were compared using one-way
ANOVA and chi-square tests. PlGF was analyzed with univariate general linear models controlling for age and sex. aP < 0.05 compared with con-
trols, bP < 0.05 compared with sMCI, cP < 0.05 compared with MCI-AD, dP < 0.05 compared with AD, eP < 0.05 compared with DLB-PDD,
fP < 0.05 compared with VaD.
Table 2. Validation cohort, demographic data, clinical characteristics,
and CSF levels of PlGF.
Control (n = 18) FTD* (n = 22)
Age 54.0 (9.2) 62.4 (7.6)a
Sex, (% female) 61% 54%
APOE
1 or 2 e4 alleles
N/A N/A
MMSE** 29.6 (0.7) 23.5 (5.2)a
PlGF, pg/mL 42.2 (19.9) 59.7 (23.9)a
F, female; FTD, frontotemporal dementia; MMSE, Mini Mental State
Examinations; PlGF, placental growth factor.
*FTD group included 14 bvFTD, 6 SD, and 2 PNFA cases (2 patients
with GRN mutation and 1 patient FTD with motor neuron disease).
**MMSE was available from 18 controls and 15 FTD patients.
Data are shown as mean (SD, n) unless otherwise specified. Differ-
ences between the groups were compared using Student’s t- and chi-
square tests; aP < 0.05 compared with controls.
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manufacturer’s protocol (Meso Scale Discovery, Gaithers-
burg, MA) with some modifications. Briefly, 10% bovine
serum albumin was added to the blocking buffer and the
samples were incubated overnight at +4°C. All samples
were measured in duplicates. Samples from the validation
and discovery cohorts were analyzed on separate occa-
sions using different PlGF assay lots. Detection limits in
the validation and discovery cohorts were 2.7 pg/mL and
3.1 pg/mL, respectively. Mean intraplate and interplate
coefficients of variance (CV) were 4.5% and 7.5% in the
discovery cohort and 5.2% and 3.3% in the validation
cohort. Intraplate CV was below 20% for all samples
except one with CV of 23%. This sample did not affect
the results and was therefore included in statistical analy-
sis. Samples were randomized according to diagnosis
across plates/runs to minimize the effects of run-to-run
variation. Our previous study has shown that PlGF levels
do not correlated with CSF storage time (unpublished
data). CSF amyloid b (Ab) 42, Ab40, and tau (total) were
analyzed with Euroimmun immunoassay (EUROIMMUN
AG, L€ubeck, Germany). CSF neurofilament light chain
(NfL) was analyzed as previously described.33
Statistical analysis
SPSS version 22 (IBM, Armonk, NY) and R version
3.3.134 was used for statistical analysis. CSF PlGF levels
were not normally distributed and therefore ln-trans-
formed before the analysis. The effects of age, sex, and
APOE genotype were tested with Pearson’s correlation
analysis and Student’s t-tests. Group differences were
assessed using Student’s t-tests, one-way ANOVA and
univariate general linear models (GLM). Linear regres-
sions were used to investigate associations with CSF Ab
and tau and clinical characteristics. Age and sex were
included in all regression models to control the con-
founding effects of these factors. Because of the relatively
small sample size we did not adjust statistical analysis for
age and sex in the validation cohort. Diagnostic accura-
cies of CSF biomarkers were assessed using receiver oper-
ating characteristic (ROC) curve analysis. Area under the
curve (AUC) of two ROC curves were compared using a
bootstrap procedure (n = 2000 iterations). Alpha-level of
significance was set at P < 0.05.
Results
Discovery cohort
Associations with demographic and clinical
characteristics
CSF levels of PlGF correlated positively with age in con-
trols (r = 0.284, P = 0.045) and in sMCI (r = 0.529,
P < 0.001), AD (r = 0.231, P = 0.046), and FTD
(r = 0.550, P = 0.003) patients and were higher in men
than women in controls (P = 0.004) and in patients with
sMCI (P = 0.011), DLB-PDD (P = 0.032), and VaD
(P = 0.011). We did not find any differences in CSF PlGF
concentrations between APOE e4 allele carriers and non-
carriers. CSF PlGF did not correlate with MMSE scores in
any of the diagnostic groups or with disease duration in
FTD group.
CSF levels of PlGF in diagnostic groups
We next compared PlGF levels between different diagnos-
tic groups using GLM adjusted for age and sex. CSF levels
of PlGF were elevated in sMCI (P = 0.019), MCI-AD
(P = 0.005), AD dementia (P < 0.001), DLB-PDD
(P < 0.001), VaD (P < 0.001), and FTD (P < 0.001) com-
pared with cognitively healthy controls (Fig. 1A and
Table 1). Notably, FTD patients showed 1.8- to 2.1-fold
higher PlGF levels compared to other dementias: AD,
DLB-PDD, and VaD (all P < 0.001, Fig. 1A and Table 1).
PlGF concentrations were also increased in FTD com-
pared to sMCI and MCI-AD (both P < 0.001, Fig. 1A
and Table 1). The results were very similar when two
patients with SD were excluded from the analysis (data
not shown).
In addition, we measured CSF levels of PlGF in another
group of 14 cognitively healthy controls and 8 patients
with FTD (Supplementary Methods and Table S1) on a
separate occasion and using different PlGF assay lot. Sim-
ilarly, we found increased levels of PlGF in FTD patients
compared to controls (P < 0.001, Fig. S1).
CSF PlGF as biomarkers of FTD
Previous studies have suggested that the CSF tau/Ab42
ratio can accurately distinguish FTD from AD dementia
(AUC 0.86-0.93).35–37 Here we compared the accuracy
of tau/Ab42, PlGF, tau/PlGF, and tau/Ab42/PlGF in
separating FTD patients from other diagnostic groups
(Table 3 and Table S2). PlGF alone showed very high
accuracies, sensitivities, and specificities when differenti-
ating FTD from both controls (AUC 0.996, sensitivity
100%, specificity 96%; Fig. 2A) and sMCI (AUC 0.954,
sensitivity 100%, specificity 84%) performing signifi-
cantly better than tau/Ab42 (AUC 0.954–0.996 vs.
0.564–0.754, P < 0.01). We did not observe any further
improvement in AUCs for tau/PlGF and tau/Ab42/
PlGF.
We then studied whether PlGF could improve the dif-
ferential diagnosis of FTD versus prodromal AD (MCI-
AD), AD dementia, and other dementia types, that is,
DLB-PDD and VaD. The performance of tau/Ab42/PlGF
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was significantly better compared to tau/Ab42 when dis-
tinguishing FTD from the group of other dementias
(AUC 0.972 vs. 0.932, P < 0.01, Fig. 2B), FTD from
DLB-PDD (AUC 0.954 vs. 0.897, P < 0.05), and FTD
from VaD (AUC 0.941 vs. 0.850, P < 0.05). In addition,
tau/Ab42/PlGF showed higher sensitivities and/or
specificities compared with tau/Ab42 for differentiating
FTD from other dementias (Table S2).
We also compared PlGF with neurofilament light chain
(NfL), another promising biomarker of neuronal damage
in FTD.38–40 In a subcohort of 267 individuals, PlGF, tau/
PlGF and/or tau/Ab42/PlGF showed higher accuracies
Figure 1. CSF levels of PlGF in dementia disorders. (A) Discovery cohort, CSF levels of PlGF in patients with AD, sMCI, MCI-AD, AD, DLB-PDD,
VaD, FTD (25 bvFTD and 2 SD) and cognitively healthy controls. (B) Validation cohort, CSF levels of PlGF in patients with FTD (14 bvFTD, 6 SD, 2
PNFA) and cognitively healthy controls. AD, Alzheimer’s disease; DLB-PDD dementia with Lewy bodies or Parkinson’s disease with dementia; FTD,
frontotemporal dementia; bvFTD, behavioral variant FTD; sMCI, stable mild cognitive impairment; MCI-AD, MCI that progressed to AD; SD,
semantic dementia; VaD, vascular dementia.
Table 3. Discovery cohort, Receiver Operating Characteristic (ROC) analysis of PlGF as a biomarker of FTD.
tau/Ab42 PlGF tau/PlGF tau/Ab42/PlGF
FTD versus controls* 0.564 (0.425–0.704) 0.996a (0.988–1.000) 0.984a (0.962–1.000) 0.946a (0.889–1.000)
FTD versus sMCI 0.754 (0.638–0.870) 0.954b (0.913–0.995) 0.962a (0.927–0.996) 0.967a (0.934–1.000)
FTD versus other dementia 0.932 (0.892–0.972) 0.905 (0.856–0.955) 0.934 (0.894–0.975) 0.972b,c,d (0.949–0.996)
FTD versus MCI-AD 0.983 (0.957–1.000) 0.981 (0.955–1.000) 0.991 (0.976–1.000) 0.999 (0.995–1.000)
FTD versus AD 0.990 (0.977–1.000) 0.925e (0.875–0.975) 0.991c (0.978–1.000) 0.997c (0.992–1.000)
FTD versus DLB-PDD 0.897 (0.828–0.966) 0.895 (0.822–0.969) 0.882 (0.806–0.958) 0.954d,e,f (0.912–0.996)
FTD versus VaD 0.850 (0.754–0.945) 0.875 (0.786–0.964) 0.881 (0.795–0.967) 0.941e (0.883–0.998)
AD, Alzheimer disease; AUC, area under the ROC curve; CI, confidence interval; DLB-PDD, dementia with Lewy bodies or Parkinson’s disease with
dementia; FTD, frontotemporal dementia; sMCI, mild cognitive impairment; MCI-AD, MCI that progressed to AD; PlGF, placental growth factor;
VaD, vascular dementia.
Data are shown as AUC (95%CI). *tau data were missing from three individuals (1 control, 1 sMCI, and 1 FTD) and these individuals were
excluded from all ROC analysis.
aP < 0.001 compared with tau/Ab42; bP < 0.01 compared with tau/Ab42; cP < 0.01 compared with PlGF; dP < 0.05 compared with tau/PlGF;
eP < 0.05 compared with tau/Ab42; fP < 0.05 compared with PlGF.
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than NfL when differentiating FTD from other dementia
groups including AD (Table S3).
Associations with CSF Ab and tau
CSF PlGF was positively associated with Ab40 in FTD
patients (b = 0.501, P = 0.020; adjusted for age and sex).
In contrast, we found a negative correlation between PlGF
and Ab42 in the controls (b = 0.354, P = 0.034; adjusted
for age and sex) but not in other groups. There were no
significant associations between CSF PlGF and tau.
Validation cohort
To confirm our findings in the discovery cohort, we mea-
sured CSF levels of PlGF in the validation cohort from
the Netherlands. Similar to the discovery cohort, we
found increased levels of PlGF in FTD patients (not
including the 5 presymptomatic individuals with GRN
mutations) compared to controls (P = 0.006, Fig. 1B,
Table 2). Notably, the differences in PlGF levels between
controls and FTD were more pronounced in the discovery
cohort. The range of CSF concentration of PlGF also dif-
fered between the two cohorts. Possible explanations for
these results might be differences in preanalytical sample
handling and lot-to-lot variation in the performance of
the PlGF kits.
The validation cohort comprised 14 bvFTD and 6 SD
patients. We found that CSF PlGF levels were increased
in bvFTD but not in SD (P = 0.006 and P = 0.200,
Fig. S2).
Finally, we measured PlGF in five presymptomatic indi-
viduals with GRN mutation. The mean PlGF concentra-
tion in this presymptomatic GRN group was almost as
high as in bvFTD (60.3  37.9 pg/mL and
63.4  25.4 pg/mL), however, the difference in the levels
between the controls and presymptomatic GRN did not
reach statistical significance (P = 0.156) most likely due
to the small sample size.
Discussion
In the discovery cohort, we demonstrated that CSF levels
of PlGF were increased in different dementia subtypes
and particularly in FTD compared to cognitively healthy
controls, with FTD patients showing 1.8- to 2.1-fold
higher PlGF concentration than individuals with AD,
DLB-PDD, and VaD. We corroborated our findings of
elevated CSF PlGF in another group of controls and FTD
patients from the same clinical center in Sweden and in
the validation cohort from the Netherlands. Furthermore,
we report that when combined with tau and Ab42, PlGF
performed better than tau/Ab42 alone in distinguishing
FTD from DLB-PDD, VaD, and all other dementias
grouped together. Finally, PlGF showed higher accuracy
than tau/Ab42 in differentiating FTD from controls and
sMCI.
These findings are in agreement with, and extend,
our previous data on increased CSF levels of PlGF in
PDD, DLB, and PD patients compared to control indi-
viduals.41 Studies investigating the role of PlGF in neu-
rodegenerative diseases are sparse and it is at present
Figure 2. ROC curve analysis in the discovery cohort. ROC curve analysis of CSF biomarkers for distinguishing FTD from controls (A) and FDT
from other dementias (B). AUC, area under the ROC curve; CI, confidence interval.
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unclear how PlGF could be linked to the core patholog-
ical features of the FTD or other dementia disorders.
Hypoxia and reactive oxygen species are strong inducers
of VEGF family members, including PlGF.42–44 Expres-
sion of PlGF is increased in mouse astrocytes and
endothelial cells following cerebral ischemia.20,21 Interest-
ingly, astrogliosis in frontal and temporal regions is one
of the core histopathological hallmarks of FTD.6 Fur-
thermore, frontotemporal lobar degeneration has been
shown to be accompanied by oxidative damage that tar-
gets primarily astrocytes.45 Thus, it is possible that in
FTD, PlGF is increased in response to astrogliosis and
oxidative stress.
In contrast to CSF Ab42 and tau, PlGF showed very
high accuracy when discriminating FTD patients from
controls and even sMCI patients (AUCs > 0.95) with the
performance similar to CSF NfL (Table S3).38–40 Although
CSF NfL is a promising biomarker of neuronal damage in
neurodegenerative disorders and disease severity in
FTD,39,40,46,47 it does not provide significant added value
to CSF Ab42 and tau for differential diagnosis of FTD
because CSF levels of NfL are also elevated in many other
dementias, for example, progressive supranuclear palsy
(PSP) and VaD.48,49 Postmortem investigations previously
indicated that 10-30% of patients clinically diagnosed
with FTD, had Alzheimer disease (AD).50–53 However, it
was later found that FTD and AD dementia differ in CSF
levels of the core AD biomarkers, Ab42 and tau: FTD
patients have consistently shown higher Ab42 and lower
tau levels compared to AD dementia patients.54–56 Fur-
thermore, several studies including one in an autopsy-
proven cohort, have reported that the tau/Ab42 (or
Ab42/tau) ratio discriminated with high sensitivity (70-
86%) and specificity (82-94%) between FTD and AD
cases.35–37 Nevertheless, there is a lack of biomarkers that
could differentiate FTD from other forms of dementia
such as, for example, DLB-PDD or VaD both of which
may share clinical symptoms with FTD.57,58 In this study,
we demonstrated that PlGF combined with tau and Ab42
(tau/Ab42/PlGF) distinguished with high accuracy
(AUCs > 0.94) FTD from DLB-PDD, VaD, and from all
other types of dementia (DLB-PDD, VaD, and AD)
grouped together performing significantly better than tau/
Ab42. While PlGF did not differentiate FTD from AD
any better than tau/Ab42, its accuracy was very high with
AUC over 0.92. Furthermore, PlGF and/or its ratios, per-
formed better than NfL when distinguishing FTD from
other dementia groups including AD. Of note, although
the diagnosis of FTD was in the first hand based on
assessment of clinical symptoms and neuroimaging find-
ings, treating physicians had access to CSF Ab42 and tau
data. Consequently, it is possible that the diagnostic per-
formance of PlGF in comparison with Ab42 and tau was
underestimated given the availability of CSF AD biomark-
ers (but not PlGF) in the diagnostic process.
One limitation of this study is that we did not measure
p-tau. Recent data have indicated that p-tau/Ab42 pre-
forms better than t-tau/Ab42 when differentiating
autopsy-confirmed frontotemporal lobar degeneration
from AD.59 Thus, future studies are needed to establish if
PlGF could further improve the accuracy of p-tau/Ab42
in distinguishing FTD from other dementias. Another
limitation is that because FTD is a rare disease the sam-
ples size was small with only few cases had autopsy-con-
firmed diagnosis. Future studies in larger cohorts of
neuropathologically confirmed cases should investigate
PlGF levels across different dementia disorders and differ-
ent clinical, pathological, and genetic FTD subtypes.
We demonstrate that CSF PlGF is increased in FTD
compared with sMCI, MCI-AD, DLB-PDD, VaD, and
control groups and that PlGF in combination with Ab42
and tau accurately differentiates FTD from other demen-
tia disorders, stable MCI patients, and cognitively healthy
controls. These results suggest that PlGF offers significant
promise as diagnostic biomarker of FTD and merit fur-
ther studies in larger clinical cohorts.
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